Study on Preparation and Corrosion Inhibition Performance of Oligomeric Supercritical CO₂ Corrosion Inhibitors
Advances in Engineering Technology Research · 20.03.2026 · 16 (1) · 121
DOI: 10.56028/aetr.16.1.121.2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Engineering Technology Research, online erschienen am 20.03.2026. Verfasst von Rongbo Ma und 1 weiteren Autor:innen.
Abstract (Originalsprache)
This work addresses the issue of poor corrosion inhibition performance of conventional corrosion inhibitors in supercritical CO₂ environments. Using oligomeric materials such as dimer acid, we synthesized a new type of oligomeric supercritical CO₂ corrosion inhibitors: oligomeric imidazoline . The influence of factors including water content, corrosion temperature, and corrosion time on the corrosion inhibition performance of different oligomeric inhibitors was investigated using a self-designed supercritical CO₂ corrosion inhibitor evaluation device. The results show that under the conditions of 7.65 MPa, 55 °C, and a corrosion time of 24 h, the corrosion inhibition efficiency of the oligomeric imidazoline inhibitor can reach up to 93.67%, indicating its excellent film-forming property, surface activity, and overall performance.
Zitieren
APA
Ma, R., & Yang, F. (2026). Study on Preparation and Corrosion Inhibition Performance of Oligomeric Supercritical CO₂ Corrosion Inhibitors. Advances in Engineering Technology Research, 16(1), 121. https://doi.org/10.56028/aetr.16.1.121.2026
Vancouver
Ma R, Yang F. Study on Preparation and Corrosion Inhibition Performance of Oligomeric Supercritical CO₂ Corrosion Inhibitors. Advances in Engineering Technology Research. 2026;16(1):121. doi:10.56028/aetr.16.1.121.2026
BibTeX
@article{Ma2026,
author = {Ma, Rongbo and Yang, Fei},
title = {Study on Preparation and Corrosion Inhibition Performance of Oligomeric Supercritical CO₂ Corrosion Inhibitors},
journal = {Advances in Engineering Technology Research},
year = {2026},
volume = {16},
number = {1},
pages = {121},
doi = {10.56028/aetr.16.1.121.2026}
}
EUVIMED